SCHEMBL6905698

SCHEMBL6905698

CCOC(=O)CN(C(C)=O)c1ccc(OC(C)=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 3/20 0.41
CYP3A4 P08684 2/20 0.41
MITF O75030 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
POLB P06746 2/20 0.39
PKM P14618 1/20 0.39
TTR P02766 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905596 0.90 LMNA (0.45) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6908413 0.89 LMNA (0.40) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL6908944 0.85 ALDH1A1 (0.46) LMNAKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL4036462 0.84 SMN1; SMN2 (0.49) KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6907787 0.83 LMNA (0.48) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL3662801 0.83 CA12 (0.47) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6906705 0.82 LMNA (0.46) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL14248928 0.82 TDP1 (0.51) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL5626939 0.82 LMNA (0.47) LMNAKMT2AMEN1ALDH1A1KDM4E
SCHEMBL6906977 0.82 ALDH1A1 (0.41) LMNAKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 LMNA 1347/4885KMT2A 1750/4885MEN1 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.